

Global Neoantigen Cancer Vaccine Market: Focus on Approach, Line of Therapy, Type, Application, Treatment Strategy, and Country-Wise Analysis - Analysis and Forecast, 2024-2031

<https://marketpublishers.com/r/G40D08258FA9EN.html>

Date: February 2022

Pages: 199

Price: US\$ 5,250.00 (Single User License)

ID: G40D08258FA9EN

Abstracts

Market Report Coverage - Neoantigen Cancer Vaccine

Market Segmentation

Product Type - Personalized and Off-the-Shelf

Type of Neovaccine - Nucleic Acid Vaccine, Peptide Vaccine, and Dendritic Cell-Based Vaccine

Therapeutic Specialty - Lung Cancer, Urinary System Cancer, Melanoma, Liver Cancer, Head and Neck Cancer, and Blood and Bone Marrow Cancer

Line of Therapy - First Line, Second Line, and Later Lines

Regional Segmentation

North America - U.S. and Canada

Europe - Germany, U.K., France, Italy, and Spain

Asia-Pacific and Middle East - China, Australia, Japan, South Korea, and Israel

Market Growth Drivers

Increasing Global Prevalence of Cancer

Increase in Adoption of Personalized Medicine to Tailor Patient's Treatment on an Individual Level

Significant External Funding for Executing Research and Development Exercise

Market Challenges

Higher Cost of Personalized Cancer Vaccines

Hurdles in Clinical Development and Optimization Process

Uncertain Reimbursement Scenario

Payer Uncertainty and Outcome-Based Pricing

High Capital Requirement Hampering the Expansion of Global Reach

Market Opportunities

Treatment Gaps

Reduced Turnaround Time and Cost

Partnerships and Collaboration between Various Healthcare Stakeholders

Data Analytics

Key Companies Profiled

Moderna Therapeutics, F. Hoffmann-La Roche Ltd, AstraZeneca plc, Agenus, OSE Immunotherapeutics, Advaxis, Medigene, Neon Therapeutics (Acquired by BioNTech SE), Genocea Biosciences, Immunovative Therapies, Gritstone Oncology, Nouscom,

NantBioScience, Immunovaccine, BioLineRx, Geneos Therapeutics

Key Questions Answered in this Report:

What are the major market drivers, challenges, and opportunities in the global neoantigen cancer vaccines market?

What are the underlying structures resulting in emerging trends within the global neoantigen cancer vaccines market?

What key development strategies are implemented by the major players in order to sustain in the competitive market?

What are the key regulatory implications in developed and developing regions for neoantigen cancer vaccines?

How each segment of the market is expected to grow during the forecast period 2024-2031, and what is the estimated revenue to be generated by each of the segments on the basis of:

Product Type (Personalized and Off-the-Shelf),

Type of Neovaccine (Nucleic Acid Vaccine, Peptide Vaccine, and Dendritic Cell-Based Vaccine)

Line of Therapy (First Line, Second Line, and Later Lines)

Region, including North America, Europe, Asia-Pacific and Middle East

Who are the leading players with significant offerings to the global neoantigen cancer vaccines market? What is the expected market dominance for each of these leading players?

Which companies are anticipated to be highly disruptive in the future and why?

What are the current treatment gaps, and how neovaccines are expected to fill these gaps?

What are the unmet needs in the global neoantigen cancer vaccine market?

Market Overview

The global neoantigen cancer vaccine industry analysis by BIS Research projects the market to grow at a significant CAGR of 77.73% during the forecast period 2024-2031. The neoantigen cancer vaccine market is expected to generate \$35.5 million in revenue in 2024, owing to the expected launch of the first neoantigen vaccine, DC vaccine in the market.

The neoantigen cancer vaccine market growth has been primarily attributed to major drivers in this market, such as rising prevalence of cancers, increasing adoption of personalized medicine to tailor patient's treatment on an individual level, and significant external funding for executing research and development exercises. However, significant challenges are restraining the market growth. These challenges include the expected higher cost of personalized cancer vaccines, hurdles in clinical development, and payer uncertainty and outcome-based pricing.

Expert Quote on the Neoantigen Cancer Vaccine Market

“The real issues with neovaccines are higher cost, turn-around times, and limited efficacy. The cost and time to manufacture have come down in the last four years, and as technology improves, it will come down more.”

The neoantigen cancer vaccine market report provides a holistic view of the market in terms of various factors influencing it, including reported clinical findings, financing and partnership opportunities, expected market, and current clinical landscape.

The scope of this report is centered upon conducting a detailed study of the products expected to be allied with the oncology market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of key players, growth potential of each underlying sub segment and company, as well as other vital information with respect to the global neoantigen cancer vaccine market.

Pipeline Segmentation

The emerging neoantigen cancer vaccines are segmented based on product type into personalized and off-the-shelf neovaccines.

The emerging neoantigen cancer vaccines are segmented based on disease/application into lung cancer, urinary system cancer, melanoma, liver cancer, head and neck cancer, and blood and bone marrow cancer.

The emerging neoantigen cancer vaccines are segmented based on type of neovaccine into nucleic acid vaccine, peptide vaccine, and dendritic cell vaccine.

The emerging neoantigen cancer vaccines are segmented based on line of therapy into first, second, and later lines therapy.

The emerging neoantigen cancer vaccines are segmented based on development phase into Phase I, II, and III.

The emerging neoantigen cancer vaccines are segmented on the basis of route-of-administration into intradermal, subcutaneous, and intramuscular administrations.

Contents

1 PRODUCT DEFINITION

1.1 Inclusion and Exclusion

2 RESEARCH SCOPE

2.1 Scope of the Study

2.2 Key Questions Answered in the Report

3 RESEARCH METHODOLOGY

3.1 Primary Data Sources

3.1.1 Secondary Data Sources

3.2 Market Estimation Model

3.2.1 Factors for Data Prediction and Modelling

3.2.2 Assumptions and Limitations

4 NEOANTIGEN CANCER VACCINE IN CANCER IMMUNOTHERAPY: OVERVIEW

4.1 Introduction

4.2 Cancer Antigens

4.3 Targeting Cancer Neoantigen: A Next Wave of Innovation in Oncology?

4.4 Neoantigen Cancer Vaccine Mechanism of Action

4.5 Types of Neoantigen Cancer Vaccine (by Product Type)

4.5.1 Personalized Cancer Vaccine

4.5.2 Off-the-Shelf Neoantigen Cancer Vaccine

4.6 Types of Neoantigen Cancer Vaccine Market (by Type of Neovaccine (Biological Platform))

4.6.1 Nucleic Acid/DNA/mRNA Vaccine

4.6.2 Peptide Vaccine

4.6.3 Dendritic Cell–Based Vaccine

4.7 Types of Neoantigen Cancer Vaccine (by Type of Delivery)

4.7.1 Lipid-Based Delivery Approaches

4.7.1.1 Peptide (SLP) Mediate Vaccine Delivery in Conjunction with an Adjuvant

4.7.1.2 Sequential Immunization of Viral Prime and RNA Boost

4.7.2 Direct Injection of Unformulated mRNA Vaccines Encoding Neoepitopes

4.7.3 Other Approaches

- 4.8 Prediction Software for Neoantigens
 - 4.8.1 Limitations of Neoantigen Prediction Process
- 4.9 Limitations of Neoantigen Cancer Vaccine
 - 4.9.1 Lower Tumor Mutational Burden
 - 4.9.2 Neoantigens Maturity
- 4.1 Future Prospects
 - 4.10.1 Multi-Epitope Vaccination
 - 4.10.2 Combinatorial Regimen with Targeted Therapies
 - 4.10.3 Combinatorial Regimen with Conventional Cancer Therapies

5 INDUSTRY INSIGHTS

- 5.1 Overview of Regulatory Pathway for Neoantigen Cancer Vaccine
 - 5.1.1 U.S. FDA Guidelines for Biologics License Application (BLA) Submission
 - 5.1.2 European Medicine Agency (EMA) Biologics License Application Process
 - 5.1.2.1 Centralized Procedure
 - 5.1.2.2 Decentralized Procedure
 - 5.1.2.3 Mutual-Recognition Procedure
- 5.2 Regulatory Challenges
- 5.3 Successful Regulatory Strategies
- 5.4 Patent Landscape

6 IMPACT OF COVID-19 ON THE GLOBAL NEOANTIGEN CANCER VACCINE MARKET

7 MARKET DYNAMICS

- 7.1 Overview
- 7.2 Emerging and Current Market Trends
- 7.3 Market Drivers
 - 7.3.1 Increasing Global Prevalence of Cancer
 - 7.3.2 Increase in Adoption of Personalized Medicine to Tailor Patient's Treatment on an Individual Level
 - 7.3.3 Significant External Funding for Executing Research and Development Exercise
- 7.4 Market Restraints
 - 7.4.1 Higher Cost of Personalized Cancer Vaccines
 - 7.4.2 Hurdles in Clinical Development and Optimization Process
 - 7.4.3 Uncertain Reimbursement Scenario
 - 7.4.4 Payer Uncertainty and Outcome-Based Pricing

- 7.4.5 High Capital Requirement Hampering the Expansion of Global Reach
- 7.5 Market Opportunities
 - 7.5.1 Treatment Gaps
 - 7.5.2 Reduced Turnaround Time and Cost
 - 7.5.3 Partnerships and Collaboration between Various Healthcare Stakeholders
 - 7.5.4 Data Analytics

8 PIPELINE LANDSCAPE

- 8.1 Emerging Neoantigen Cancer Vaccine
- 8.2 Clinical Trials Heat Map
- 8.3 Pipeline Analysis
 - 8.3.1 By Development Phase
 - 8.3.2 By Type of Therapy
 - 8.3.3 By Product Type
 - 8.3.4 By Treatment Strategy
 - 8.3.5 By Type of Neovaccine
 - 8.3.6 By Delivery Approach
 - 8.3.7 By Line of Therapy
 - 8.3.8 By Therapeutic Specialty
 - 8.3.9 By Route of Administration
 - 8.3.10 By Core Product Status
 - 8.3.11 By Neoantigen Payload

9 GLOBAL NEOANTIGEN CANCER VACCINE MARKET (BY PRODUCT TYPE)

- 9.1 Personalized Neoantigen Cancer Vaccine
- 9.2 Off-the-Shelf Neoantigen Cancer Vaccine

10 GLOBAL NEOANTIGEN CANCER VACCINE MARKET (BY PIPELINE PRODUCT)

- 10.1 Tedopi
- 10.2 Allovox
- 10.3 DC (Dendritic Cells) Vaccine
- 10.4 ADXS-Neo
- 10.5 GEN-009
- 10.6 RG6180

11 GLOBAL NEOANTIGEN CANCER VACCINE MARKET (BY TYPE OF

NEOVACCINE)

11.1 Nucleic Acid (DNA/RNA Vaccine)

11.1.1 DNA Vaccine

11.1.2 RNA Vaccine

11.2 Peptide Vaccines

11.3 Dendritic Cell-Based Vaccine

12 GLOBAL NEOANTIGEN CANCER VACCINE MARKET (BY LINE OF THERAPY)

12.1 First Line Neovaccine Regimens

12.2 Second Line Neovaccine Regimens

12.3 Later Lines Neovaccine Regimens

13 GLOBAL NEOANTIGEN CANCER VACCINE MARKET (BY THERAPEUTIC SPECIALTY), 2024-2031

13.1 Melanoma

13.2 Lung Cancer

13.3 Urinary System Cancer

13.4 Liver Cancer

13.5 Head and Neck Cancer

13.6 Blood and Bone Marrow Cancer

14 GLOBAL NEOANTIGEN CANCER VACCINE MARKET (BY REGION)

14.1 Overview

14.2 North America

14.3 U.S.

14.3.1 Market Size and Forecast

14.4 Canada

14.4.1 Market Size and Forecast

14.5 Europe

14.5.1 Germany

14.5.1.1 Market Size and Forecast

14.5.2 France

14.5.2.1 Market Size and Forecast

14.5.3 U.K.

14.5.3.1 Market Size and Forecast

14.5.4 Italy

14.5.4.1 Market Size and Forecast

14.5.5 Spain

14.5.5.1 Market Size and Forecast

14.6 Asia-Pacific and Middle East

14.6.1 Japan

14.6.1.1 Market Size and Forecast

14.6.2 China

14.6.2.1 Market Size and Forecast

14.6.3 Australia

14.6.3.1 Market Size and Forecast

14.6.4 South Korea

14.6.4.1 Market Size and Forecast

14.6.5 Israel

14.6.5.1 Market Size and Forecast

15 COMPETITIVE LANDSCAPE

15.1 Overview

15.2 Key Developments and Strategies

15.2.1 Partnerships and Alliances

15.2.2 Business Expansions

15.2.3 Merger and Acquisition Activities

15.2.4 Product Approvals

15.2.5 Financing Activities

15.2.6 Funding Activities

15.2.7 Regulatory and Legal Activities

16 COMPANY PROFILES

16.1 Moderna Therapeutics

16.1.1 Company Overview

16.1.2 Role of Moderna Therapeutics in the Global Neoantigen Cancer Vaccine Market

16.1.3 Technology and Capabilities

16.1.4 Financials

16.1.5 Key Insights about Financial Health of the Company

16.1.6 SWOT Analysis:

16.2 F. Hoffmann-La Roche Ltd

- 16.2.1 Company Overview
- 16.2.2 Role of F. Hoffmann-La Roche Ltd in the Global Neoantigen Cancer Vaccine Market
- 16.2.3 Technology and Capabilities
 - 16.2.3.1 Technology Platform
 - 16.2.3.2 Manufacturing
- 16.2.4 Financials
- 16.2.5 Key Insights about Financial Health of the Company
- 16.2.6 SWOT Analysis:
- 16.3 AstraZeneca plc
 - 16.3.1 Company Overview
 - 16.3.2 Role of AstraZeneca plc in the Global Neoantigen Cancer Vaccine Market
 - 16.3.3 Financials
 - 16.3.4 Key Insights about Financial Health of the Company
 - 16.3.5 SWOT Analysis:
- 16.4 Agenus
 - 16.4.1 Company Overview
 - 16.4.2 Role of Agenus in the Global Neoantigen Cancer Vaccine Market
 - 16.4.3 Technology and Capabilities
 - 16.4.3.1 Technology Platforms
 - 16.4.3.2 Manufacturing
 - 16.4.3.3 Adjuvant
 - 16.4.4 Financials
 - 16.4.5 Key Insights about Financial Health of the Company
 - 16.4.6 SWOT Analysis:
- 16.5 OSE Immunotherapeutics
 - 16.5.1 Company Overview
 - 16.5.2 Role of OSE Immunotherapeutics in the Global Neoantigen Cancer Vaccine Market
 - 16.5.3 Technology and Capabilities
 - 16.5.3.1 Technology Platforms
 - 16.5.3.2 Manufacturing
 - 16.5.4 Financials
 - 16.5.5 Key Insights about Financial Health of the Company
 - 16.5.6 SWOT Analysis:
- 16.6 Advaxis
 - 16.6.1 Company Overview
 - 16.6.2 Role of Advaxis in the Global Neoantigen Cancer Vaccine Market
 - 16.6.3 Technology and Capabilities

- 16.6.3.1 Technology platform
- 16.6.3.2 Manufacturing
- 16.6.4 Financials
- 16.6.5 Key Insights about Financial Health of the Company
- 16.6.6 SWOT Analysis:
- 16.7 Medigene
 - 16.7.1 Company Overview
 - 16.7.2 Role of Medigene in the Global Neoantigen Cancer Vaccine Market
 - 16.7.3 Technology and Capabilities
 - 16.7.3.1 Technology Platform
 - 16.7.3.2 Manufacturing
 - 16.7.4 Financials
 - 16.7.5 Key Insights about Financial Health of the Company
 - 16.7.6 SWOT Analysis:
- 16.8 Neon Therapeutics (Acquired by BioNTech SE)
 - 16.8.1 Company Overview
 - 16.8.2 Role of Neon Therapeutics (Acquired by BioNTech SE) in the Global Neoantigen Cancer Vaccine Market
 - 16.8.3 Technology and Capabilities
 - 16.8.3.1 Technology Platforms
 - 16.8.3.2 Manufacturing
 - 16.8.4 SWOT Analysis:
- 16.9 Genocea Biosciences
 - 16.9.1 Company Overview
 - 16.9.2 Role of Genocea Biosciences in the Global Neoantigen Cancer Vaccine Market
 - 16.9.3 Technology and Capabilities
 - 16.9.3.1 Technology Platform
 - 16.9.3.2 Manufacturing Capabilities
 - 16.9.4 SWOT Analysis:
- 16.1 Immunovative Therapies
 - 16.10.1 Company Overview
 - 16.10.2 Role of Immunovative Therapies in the Global Neoantigen Cancer Vaccine Market
 - 16.10.3 Technology and Capabilities
 - 16.10.3.1 Technology Platform
 - 16.10.3.2 Manufacturing
 - 16.10.4 SWOT Analysis:
- 16.11 Gritstone Oncology
 - 16.11.1 Company Overview

- 16.11.2 Role of Gritstone Oncology in the Global Neoantigen Cancer Vaccine Market
- 16.11.3 Technology and Capabilities
 - 16.11.3.1 Technology Platform
 - 16.11.3.2 Manufacturing
- 16.11.4 SWOT Analysis:
- 16.12 Nouscom
 - 16.12.1 Company Overview
 - 16.12.2 Role of Nouscom in the Global Neoantigen Cancer Vaccine Market
 - 16.12.3 Technology and Capabilities
 - 16.12.3.1 Technology Platform
 - 16.12.3.2 Manufacturing
 - 16.12.4 SWOT Analysis:
- 16.13 NantBioScience
 - 16.13.1 Company Overview
 - 16.13.2 Role of NantBioScience in the Global Neoantigen Cancer Vaccine Market
 - 16.13.3 SWOT Analysis:
- 16.14 Immunovaccine
 - 16.14.1 Company Overview
 - 16.14.2 Role of Immunovaccine in the Global Neoantigen Cancer Vaccine Market
 - 16.14.3 SWOT Analysis:
- 16.15 BioLineRx
 - 16.15.1 Company Overview
 - 16.15.2 Role of BioLineRx in the Global Neoantigen Cancer Vaccine Market
 - 16.15.3 SWOT Analysis:
- 16.16 Geneos Therapeutics
 - 16.16.1 Company Overview
 - 16.16.2 Role of Geneos Therapeutics in the Global Neoantigen Cancer Vaccine Market
 - 16.16.3 SWOT Analysis:

List Of Figures

LIST OF FIGURES

Figure 1: Impact Analysis of Market Drivers and Market Restraints on the Global Neoantigen Cancer Vaccine Market

Figure 2: Global Neoantigen Cancer Vaccine Market Size (by Product Type), \$Million, 2024 and 2031

Figure 3: Global Neoantigen Cancer Vaccine Market (by Type of Neovaccine), \$Million, 2024 and 2031

Figure 4: Global Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), \$Million, 2024 and 2031

Figure 5: Global Neoantigen Cancer Vaccine Market (by Line of Therapy), \$Million, 2024 and 2031

Figure 6: Global Neoantigen Cancer Vaccine Market (by Region), \$Million, 2024 and 2031

Figure 7: Global Neoantigen Cancer Vaccine Market Segmentation

Figure 8: Global Neoantigen Cancer Vaccine Market: Existing Pipeline Segmentation

Figure 9: Global Neoantigen Cancer Vaccine Market Research Methodology

Figure 10: Primary Research Methodology

Figure 11: Bottom-Up Approach (Segment-Wise Analysis)

Figure 12: Step by Step Approach

Figure 13: Step by Step Process for Neoantigen Vaccine Development

Figure 14: Type of Cancer Antigens

Figure 15: Specialized Therapies Segmentation in the U.S.

Figure 16: Neoantigen Cancer Vaccine Mechanism of Action

Figure 17: Factors Affecting Neoantigen Prediction Process

Figure 18: Future Prospects of Neovaccines

Figure 19: U.S. FDA Review Timeline

Figure 20: EMA Review Timeline

Figure 21: Share of Patents (by Ownership), 2016-2019

Figure 22: Number of Deaths Due to Different Cancer Types, Million, 2020

Figure 23: Global Cancer Incidence, Million, 2018

Figure 24: Neovaccines Funding and Expansion Activities Breakout, January 2016-September 2019

Figure 25: Overall Financing Raised by Emerging Neovaccine Companies, \$Million, January 2016-September 2019

Figure 26: Overview of Reimbursement Policies in Europe

Figure 27: Market Opportunities

Figure 28: Key Neoantigen Cancer Vaccine in Clinical Development Phase I, II and III, 2021

Figure 29: Neoantigen Cancer Vaccine: Clinical Trials Heat Map

Figure 30: Neoantigen Cancer Vaccine: Breakdown of Pipeline (by Development Phase), 2021

Figure 31: Neoantigen Cancer Vaccine (by Type of Therapy)

Figure 32: Neoantigen Cancer Vaccine (by Product Type)

Figure 33: Neoantigen Cancer Vaccine (by Treatment Strategy)

Figure 34: Neoantigen Cancer Vaccine (by Type of Neovaccine (Biological Platform))

Figure 35: Neoantigen Cancer Vaccine (by Delivery Approach)

Figure 36: Neoantigen Cancer Vaccine, by Line of Therapy

Figure 37: Number of Neoantigen Cancer Vaccine (by Oncology Speciality)

Figure 38: Neoantigen Cancer Vaccine (by Route of Administration)

Figure 39: Neoantigen Cancer Vaccine (by Core Product Status)

Figure 40: Neoantigen Cancer Vaccine (by Neoantigen Payload)

Figure 41: Revenue Contribution of Different Segments (by Product Type), \$Million, 2024 and 2031

Figure 42: Personalized Neoantigen Cancer Vaccine Market (by Product Type), \$Million, 2024-2031

Figure 43: Off-the-Shelf Neoantigen Cancer Vaccine Market (by Product Type), \$Million, 2024-2031

Figure 44: Revenue Contribution of Different Segments (by Pipeline), \$Million, 2024 and 2031

Figure 45: Tedopi-Neoantigen Cancer Vaccine Market (by Pipeline), \$Million, 2024-2031

Figure 46: Allovox-Neoantigen Cancer Vaccine Market (by Pipeline), \$Million, 2024-2031

Figure 47: DC (Dendritic Cells) Vaccine-Neoantigen Cancer Vaccine Market (by Pipeline), \$Million, 2024-2031

Figure 48: ADXS-Neo-Neoantigen Cancer Vaccine Market (by Pipeline), \$Million, 2024-2031

Figure 49: GEN-009-Neoantigen Cancer Vaccine Market (by Pipeline), \$Million, 2024-2031

Figure 50: RG6180-Neoantigen Cancer Vaccine Market (by Pipeline), \$Million, 2024-2031

Figure 51: Revenue Contribution of Different Segments (by Type of Neovaccine), \$Million, 2024 and 2031

Figure 52: DNA-Based Neoantigen Cancer Vaccine Market (Nucleic Acid, by Type of Neovaccine), \$Million, 2024-2031

Figure 53: RNA-Based Neoantigen Cancer Vaccine Market (Nucleic Acid, by Type of Neovaccine), \$Million, 2024-2031

Figure 54: Peptide Neoantigen Cancer Vaccine Market (by Type of Neovaccine), \$Million, 2024-2031

Figure 55: Dendritic Cell-Based Neoantigen Cancer Vaccine Market (by Type of Neovaccine), \$Million, 2024-2031

Figure 56: Revenue Contribution of Different Segments (by Line of Therapy), \$Million, 2024 and 2031

Figure 57: First Line Neoantigen Cancer Vaccine Market (by Line of Therapy), \$Million, 2024-2031

Figure 58: Second Line Neoantigen Cancer Vaccine Market (by Line of Therapy), \$Million, 2024-2031

Figure 59: Later Lines Neoantigen Cancer Vaccine Market (by Line of Therapy), \$Million, 2024-2031

Figure 60: Melanoma Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), \$Million, 2024-2031

Figure 61: Lung Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), \$Million, 2024-2031

Figure 62: Urinary System Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), \$Million, 2024-2031

Figure 63: Liver Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), \$Million, 2024-2031

Figure 64: Head and Neck Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), \$Million, 2024-2031

Figure 65: Blood and Bone Marrow Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), \$Million, 2024-2031

Figure 66: Global Neoantigen Cancer Vaccine Market (by Region)

Figure 67: Global Neoantigen Cancer Vaccine Market (by Region), \$Million, 2024 and 2031

Figure 68: Global Neoantigen Cancer Vaccine Market (by Region), \$Million, 2024-2031

Figure 69: North America: Market Dynamics

Figure 70: North America Neoantigen Cancer Vaccine Market, \$Million, 2024-2031

Figure 71: North America Neoantigen Cancer Vaccine Revenue Contribution (by Country), \$Million, 2024 and 2031

Figure 72: Projections of the Older Adult Population in the U.S., Million, 2016-2060

Figure 73: U.S. Neoantigen Cancer Vaccine Market, \$Million, 2024-2031

Figure 74: Canada Neoantigen Cancer Vaccine Market, \$Million, 2024-2031

Figure 75: Europe: Market Dynamics

Figure 76: Europe Neoantigen Cancer Vaccine Market, \$Million, 2024-2031

Figure 77: Europe Neoantigen Cancer Vaccine Revenue Contribution (by Country), \$Million, 2024 and 2031

Figure 78: Germany Neoantigen Cancer Vaccine Market, \$Million, 2024-2031

Figure 79: France Neoantigen Cancer Vaccine Market, \$Million, 2024-2031

Figure 80: U.K. Neoantigen Cancer Vaccine Market, \$Million, 2024-2031

Figure 81: Italy Neoantigen Cancer Vaccine Market, \$Million, 2024-2031

Figure 82: Spain Neoantigen Cancer Vaccine Market, \$Million, 2024-2031

Figure 83: Asia-Pacific: Market Dynamics

Figure 84: Asia-Pacific Neoantigen Cancer Vaccine Market, \$Million, 2024-2031

Figure 85: Asia-Pacific and Middle East Revenue Contributions of Various Countries, \$Million, 2024 and 2031

Figure 86: Japan Neoantigen Cancer Vaccine Market, \$Million, 2024-2031

Figure 87: China Neoantigen Cancer Vaccine Market, \$Million, 2024-2031

Figure 88: Australia Neoantigen Cancer Vaccine Market, \$Million, 2024-2031

Figure 89: South Korea Neoantigen Cancer Vaccine Market, \$Million, 2024-2031

Figure 90: Israel Neoantigen Cancer Vaccine Market, \$Million, 2024-2031

Figure 91: Share of Key Developments and Strategies, January 2016-November 2021

Figure 92: Partnerships and Alliances (by Company), January 2016-November 2021

Figure 93: Business Expansions (by Company), January 2016-November 2021

Figure 94: Merger and Acquisition Activities (by Company), January 2016-November 2021

Figure 95: Product Approvals (by Company), January 2016-November 2021

Figure 96: Financing Activities (by Company), January 2016-November 2021

Figure 97: Funding Activities (by Company), January 2016-November 2021

Figure 98: Regulatory and Legal Activities (by Company), January 2016-November 2021

Figure 99: Moderna Therapeutics: Technology and Capabilities

Figure 100: Moderna Therapeutics: Therapeutic Focus Segmentation

Figure 101: Moderna Therapeutics: Overall Financials/Revenue, \$Million, 2018-2020

Figure 102: Moderna Therapeutics.: R&D Expenditure, \$Million, 2018-2020

Figure 103: Moderna Therapeutics: SWOT Analysis

Figure 104: F. Hoffmann-La Roche Ltd: Overall Product Portfolio

Figure 105: F. Hoffmann-La Roche Ltd: Overall Financials/Revenue, \$Billion, 2018-2020

Figure 106: F. Hoffmann-La Roche Ltd: Revenue (by Segment), \$Billion, 2018-2020

Figure 107: F. Hoffmann-La Roche Ltd: Revenue (by Region), \$Billion, 2018-2020

Figure 108: F. Hoffmann-La Roche Ltd: R&D Expenditure, \$Billion, 2018-2020

Figure 109: F. Hoffmann-La Roche Ltd: SWOT Analysis

Figure 110: AstraZeneca plc: Therapeutic Focus Segmentation

- Figure 111: AstraZeneca plc: Overall Financials/Revenue, \$Billion, 2018-2020
- Figure 112: AstraZeneca plc: Net Revenue (by Region), \$Billion, 2018-2020
- Figure 113: AstraZeneca plc: R&D Expenditure, \$Billion, 2018-2020
- Figure 114: AstraZeneca plc: SWOT Analysis
- Figure 115: Agenesis: Technology and Capabilities (as Per Type of Product)
- Figure 116: Agenesis: Therapeutic Focus Segmentation
- Figure 117: Agenesis: Overall Financials/Revenue, \$Million, 2018-2020
- Figure 118: Agenesis: R&D Expenditure, \$Million, 2018-2020
- Figure 119: Agenesis: SWOT Analysis
- Figure 120: OSE Immunotherapeutics: Therapeutic Focus Segmentation
- Figure 121: OSE Immunotherapeutics: Overall Financials/Revenue, \$Million, 2018-2020
- Figure 122: OSE Immunotherapeutics: R&D Expenditure, \$Million, 2016-2018
- Figure 123: OSE Immunotherapeutics: SWOT Analysis
- Figure 124: Advaxis: Therapeutic Focus Segmentation
- Figure 125: Advaxis: Overall Financials/Revenue, \$Million, 2018-2020
- Figure 126: Advaxis: R&D Expenditure, \$Million, 2018-2020
- Figure 127: Advaxis: SWOT Analysis
- Figure 128: Medigene: Therapeutic Focus Segmentation
- Figure 129: Medigene: Overall Financials/Revenue, \$Million, 2018-2020
- Figure 130: Medigene: R&D Expenditure, \$Million, 2018-2020
- Figure 131: Medigene: SWOT Analysis
- Figure 132: Neon Therapeutics: Therapeutic Focus Segmentation (Available From FY2019)
- Figure 133: Neon Therapeutics (Acquired by BioNTech): SWOT Analysis
- Figure 134: Genocea Biosciences: Therapeutic Focus Segmentation
- Figure 135: Genocea Biosciences: SWOT Analysis
- Figure 136: Immunovative Therapies: SWOT Analysis
- Figure 137: Gritstone Oncology: Therapeutic Focus Segmentation
- Figure 138: Gritstone Oncology: SWOT Analysis
- Figure 139: Nouscom: Therapeutic Focus Segmentation (Available from FY2019)
- Figure 140: Nouscom: SWOT Analysis
- Figure 141: NantBioScience: SWOT Analysis
- Figure 142: Immunovaccine: SWOT Analysis
- Figure 143: BioLineRx: SWOT Analysis
- Figure 144: Geneos Therapeutics: SWOT Analysis

List Of Tables

LIST OF TABLES

- Table 1: Implications of Personalized Cancer Vaccines (PCVs)
- Table 2: Implications of Off-the-Shelf Neoantigen Cancer Vaccine
- Table 3: Implications of DNA and RNA Vaccines
- Table 4: Implications of Peptide Vaccine
- Table 5: Implications of Dendritic Cell Vaccine
- Table 6: Prediction Software Utilized by Various Companies
- Table 7: Neoantigen Cancer Vaccines Patent Landscape, by 2019
- Table 8: Neoantigen Cancer Vaccine (by Type of Therapy)
- Table 9: Neoantigen Cancer Vaccine (by Line of Therapy)
- Table 10: Neoantigen Cancer Vaccine (by Route of Administration)
- Table 11: Neoantigen Cancer Vaccine (by Core Product Type (Licensed Products/ Technology Only))
- Table 12: Neoantigen Cancer Vaccine (by Neoantigen Payload)
- Table 13: Neoantigen Cancer Vaccine for Melanoma: Pipeline Products
- Table 14: Neoantigen Cancer Vaccine for Lung Cancer: Pipeline Products
- Table 15: Neoantigen Cancer Vaccine for Urinary Cancer: Pipeline Products
- Table 16: Neoantigen Cancer Vaccine for Head and Neck Cancer: Pipeline Products
- Table 17: Neoantigen Cancer Vaccine for Blood and Bone Marrow Cancer: Pipeline Products

I would like to order

Product name: Global Neoantigen Cancer Vaccine Market: Focus on Approach, Line of Therapy, Type, Application, Treatment Strategy, and Country-Wise Analysis - Analysis and Forecast, 2024-2031

Product link: <https://marketpublishers.com/r/G40D08258FA9EN.html>

Price: US\$ 5,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G40D08258FA9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970